Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Camilla, Pilati"'
Autor:
Sophie Mouillet-Richard, Angélique Gougelet, Bruno Passet, Camille Brochard, Delphine Le Corre, Caterina Luana Pitasi, Camille Joubel, Marine Sroussi, Claire Gallois, Julien Lavergne, Johan Castille, Marthe Vilotte, Nathalie Daniel-Carlier, Camilla Pilati, Aurélien de Reyniès, Fatima Djouadi, Sabine Colnot, Thierry André, Julien Taieb, Jean-Luc Vilotte, Béatrice Romagnolo, Pierre Laurent-Puig
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-17 (2024)
Abstract Background The mesenchymal subtype of colorectal cancer (CRC), associated with poor prognosis, is characterized by abundant expression of the cellular prion protein PrPC, which represents a candidate therapeutic target. How PrPC is induced i
Externí odkaz:
https://doaj.org/article/6c482fe7bb844cb5b3a5a20ec371350b
Autor:
Delphine Le Corre, Alexandre Ghazi, Ralyath Balogoun, Camilla Pilati, Thomas Aparicio, Séverine Martin-Lannerée, Laetitia Marisa, Fatima Djouadi, Virginie Poindessous, Carole Crozet, Jean-François Emile, Claire Mulot, Karine Le Malicot, Valérie Boige, Hélène Blons, Aurélien de Reynies, Julien Taieb, François Ghiringhelli, Jaafar Bennouna, Jean-Marie Launay, Pierre Laurent-Puig, Sophie Mouillet-Richard
Publikováno v:
EBioMedicine, Vol 46, Iss , Pp 94-104 (2019)
Background: Comprehensive transcriptomic analyses have shown that colorectal cancer (CRC) is heterogeneous and have led to the definition of molecular subtypes among which the stem-cell, mesenchymal-like group is associated with poor prognosis. The m
Externí odkaz:
https://doaj.org/article/40447755c68848f595bfc79fb34694ff
Autor:
Rita T. Lawlor, Nicola Veronese, Antonio Pea, Alessia Nottegar, Lee Smith, Camilla Pilati, Jacopo Demurtas, Matteo Fassan, Liang Cheng, Claudio Luchini
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described
Externí odkaz:
https://doaj.org/article/ea2c4117ae884f8582e4344556ef2070
Autor:
Alexandre Ghazi, Delphine Le Corre, Camilla Pilati, Julien Taieb, Thomas Aparicio, Audrey Didelot, Shoukat Dedhar, Claire Mulot, Karine Le Malicot, Fatima Djouadi, Aurélien de Reynies, Jean-Marie Launay, Pierre Laurent-Puig, Sophie Mouillet-Richard
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
The CMS4 mesenchymal subtype of colorectal cancer (CRC) is associated with poor prognosis and resistance to treatment. The cellular prion protein PrPC is overexpressed in CMS4 tumors and controls the expression of a panel of CMS4-specific genes in CR
Externí odkaz:
https://doaj.org/article/86b39e402fcf4815994a65717845a5aa
Autor:
Sophie Mouillet-Richard, Séverine Martin-Lannerée, Delphine Le Corre, Théo Z. Hirsch, Alexandre Ghazi, Marine Sroussi, Camilla Pilati, Aurélien de Reyniès, Fatima Djouadi, Nicolas Vodovar, Jean-Marie Launay, Pierre Laurent-Puig
Publikováno v:
Oncogene. 41:4397-4404
The cellular prion protein PrPC partners with caveolin-1 (CAV1) in neurodegenerative diseases but whether this interplay occurs in cancer has never been investigated. By leveraging patient and cell line datasets, we uncover a molecular link between P
Autor:
Dominique Padovani, Assia Hessani, Francine T. Castillo, Géraldine Liot, Mireille Andriamihaja, Annaïg Lan, Camilla Pilati, François Blachier, Suvajit Sen, Erwan Galardon, Isabelle Artaud
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
High levels of homocysteine in cells are linked to pathological states. Here, the authors report that homocysteine inactivates catalase by modifying the heme group, impairing cellular redox homeostasis, and show that this modification occurs in cance
Externí odkaz:
https://doaj.org/article/5c40bd245f7547b1967ae36a14dcbecc
Autor:
Jochen H.M. Prehn, Markus Rehm, Daniel B. Longley, Bryan T. Hennessy, Sandra Van Schaeybroeck, Pierre Laurent-Puig, Elaine W. Kay, Deborah A. McNamara, Manuel Salto-Tellez, Sophie Camilleri-Broët, Richard Wilson, Patrick G. Johnston, Mark Lawler, Sinead Toomey, Lisa M. Schöller, Elisabeth Zink, Camilla Pilati, Nadege Rice, Sonali Dasgupta, Lorna Flanagan, Robert O'Byrne, Áine C. Murphy, Alexa J. Resler, Orna Bacon, Andreas U. Lindner, Mattia Cremona, Sarah Curry, Clare Morgan, Maximilian L. Würstle, Manuela Salvucci
Kaplan-Meier estimates for disease-free and overall survival for n=120 stage III patients of the discovery cohort categorized based on TN staging, tumor location and lymphovascular invasion. Additional exploratory analyses investigated the prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1488d2cdef5cadeea2cb68710bd133f5
https://doi.org/10.1158/1078-0432.22467311.v1
https://doi.org/10.1158/1078-0432.22467311.v1
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
Patient characteristics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d730ee8d35666ac4f7fd891c80729e6d
https://doi.org/10.1158/1078-0432.22454784
https://doi.org/10.1158/1078-0432.22454784
Autor:
Jochen H.M. Prehn, Markus Rehm, Daniel B. Longley, Bryan T. Hennessy, Sandra Van Schaeybroeck, Pierre Laurent-Puig, Elaine W. Kay, Deborah A. McNamara, Manuel Salto-Tellez, Sophie Camilleri-Broët, Richard Wilson, Patrick G. Johnston, Mark Lawler, Sinead Toomey, Lisa M. Schöller, Elisabeth Zink, Camilla Pilati, Nadege Rice, Sonali Dasgupta, Lorna Flanagan, Robert O'Byrne, Áine C. Murphy, Alexa J. Resler, Orna Bacon, Andreas U. Lindner, Mattia Cremona, Sarah Curry, Clare Morgan, Maximilian L. Würstle, Manuela Salvucci
Unadjusted and multivariate Cox proportional hazards analyses to examine the association of APOPTO-CELL and APOPTO-CELL-PC3 signatures with DFS in n=157 stage III patients of the expansion cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0401b46937d32b10574be283b4f4e5d9
https://doi.org/10.1158/1078-0432.22467290.v1
https://doi.org/10.1158/1078-0432.22467290.v1
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
(A) Median progression-free survival according to type of therapy in the KRAS and BRAF mutated KRAS 3'-UTR LCS6 SNP carriers, (B) Median progression-free survival according to type of therapy in the KRAS and BRAF mutated non-KRAS 3'-UTR LCS6 SNP carr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56dd150c6033ab1d6f7c9ec6ffe55646
https://doi.org/10.1158/1078-0432.22454787
https://doi.org/10.1158/1078-0432.22454787